Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Evexia Wealth LLC

Evexia Wealth LLC increased its position in Becton, Dickinson and Company (NYSE:BDX) by 4.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,898 shares of the medical instruments supplier’s stock after buying an additional 1,086 shares during the period. Becton, Dickinson and Company comprises 2.4% of Evexia Wealth LLC’s portfolio, making the stock its 19th largest holding. Evexia Wealth LLC’s holdings in Becton, Dickinson and Company were worth $5,668,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of BDX. Ontario Teachers Pension Plan Board raised its holdings in Becton, Dickinson and Company by 242.8% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after acquiring an additional 1,263,391 shares during the last quarter. Vanguard Group Inc. lifted its position in Becton, Dickinson and Company by 2.0% during the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after buying an additional 516,427 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in Becton, Dickinson and Company by 11.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock worth $1,342,503,000 after buying an additional 512,566 shares during the last quarter. Royal Bank of Canada boosted its stake in Becton, Dickinson and Company by 28.5% in the 3rd quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock worth $553,121,000 after buying an additional 473,914 shares during the last quarter. Finally, Morgan Stanley grew its holdings in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after buying an additional 435,168 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.2 %

Becton, Dickinson and Company stock traded up $0.56 during midday trading on Tuesday, reaching $237.14. The stock had a trading volume of 1,120,070 shares, compared to its average volume of 1,408,706. The stock’s 50-day simple moving average is $238.27 and its 200 day simple moving average is $239.97. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The stock has a market capitalization of $68.54 billion, a PE ratio of 52.23, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.86 EPS. Analysts expect that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Analyst Upgrades and Downgrades

Separately, Barclays increased their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average price target of $281.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.